Search
Jun 1
The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease
Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.
Jun 7, 2023
Talking oncology targets (EGFR, FLT3, B7H4 and more) with Cullinan Oncology
Cullinan Oncology CEO Nadim Ahmed walks us through the oncology targets the company is focused on and discusses recent ASCO data.